These changes include the up-regulation of CD73, a down-regulation of ADA activity, and elevations in the A2BR. It provides proof of concept information that human COPD and IPF patients may benefit from adenosine-based therapeutics such as ADA enzyme replacement therapy or treatment with an A2BR antagonist. This evidence concerns the gene ADA and chronic obstructive pulmonary disease.